Edgewise Therapeutics Overview
Edgewise Therapeutics Target Price
Analysts' average 12-month price target for Edgewise Therapeutics is $50.
Get informed when a big investor buys or sells
+ FollowShare Price
$44.4
Average Target Price
$49.73
12% upside
12% upside11 analysts in the last 4 months
High: $66 | Low: $32
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2026-08-11 | Goldman Sachs | $36 |  18.9% downside |  |
| 2026-07-20 | Evercore ISICory Kasimov | $55 | 23.9% upside | |
| 2026-07-09 | Oppenheimer | $51 | 14.9% upside | |
| 2026-07-06 | GuggenheimDebjit Chattopadhyay | $51 | 14.9% upside | |
| 2026-06-17 | RBC Capital | $59 | 32.9% upside | |
| 2026-06-17 | Goldman SachsPaul Choi | $32 | 27.9% downside | |
| 2026-06-16 | Leerink Partners | $52 | 17.1% upside | |
| 2026-06-02 | H.C. Wainwright | $45 | 1.4% upside | |
| 2026-06-02 | RBC CapitalLeonid Timashev | $48 | 8.1% upside | |
| 2026-06-01 | Raymond JamesMartin Auster | $66 | 48.6% upside | |
| 2026-06-01 | WedbushLaura Chico | $52 | 17.1% upside | |
| 2026-05-06 | Truist Financial | $52 | 17.1% upside | |
| 2026-03-10 | Raymond JamesMartin Auster | $46 | 3.6% upside | |
| 2026-02-26 | Evercore ISICory Kasimov | $45 | 1.4% upside | |
| 2026-02-26 | Stifel NicolausJames Condulis | $25 | 43.7% downside | |
| 2025-09-24 | Goldman Sachs | $20 | 55% downside | |
| 2025-03-07 | Scotiabank | $50 | 12.6% upside | |
| 2024-12-05 | Truist FinancialSrikripa Devarakonda | $50 | 12.6% upside | |
| 2024-10-11 | Piper SandlerYasmeen Rahimi | $51 | 14.9% upside | |
| 2024-09-20 | RBC CapitalLeonid Timashev | $42 | 5.4% downside | |
| 2024-09-19 | Leerink PartnersJoseph Schwartz | $42 | 5.4% downside | |
| 2024-07-01 | Piper SandlerYasmeen Rahimi | $48 | 8.1% upside | |